Anixa Reports Positive Phase 1 Breast Cancer Vaccine Data
Anixa Biosciences announced positive Phase 1 data for its investigational breast cancer vaccine, showing strong safety and immune response results in 74% of participants.
/ 19 items
#MRK↓
Key Pharma Stock Updates: Merck, BeOne, MeiraGTx, MannKind, and Fulcrum
Wells Fargo upgrades Merck to Overweight; Truist and H.C. Wainwright initiate coverage on BeOne Medicines, MeiraGTx, MannKind, and Fulcrum with Buy ratings and promising price targets.
FDA Approves Keytruda + Padcev Combo for Bladder Cancer Surgery Patients
FDA approves groundbreaking Keytruda (MRK) and Padcev (PFE) combination as first perioperative treatment for muscle-invasive bladder cancer patients who can't receive chemotherapy.
Merck’s WINREVAIR Met Primary Endpoint in Combined Pulmonary Hypertension
Merck’s WINREVAIR met its goal in a Phase 2 study for CpcPH, a tough heart/lung disease. It helps blood move through the lungs better.
Merck's $9.2B Cidara Takeover: Big Pharma's Fight for Flu Innovation
Merck wins bidding war for Cidara Therapeutics at $9.2B, more than double its market value, securing groundbreaking long-acting flu antibody treatment as Big Pharma races for cutting-edge medicines.
Neuphoria Explores Sale Options After Drug Trial Failure
Neuphoria Therapeutics initiates strategic review following failed clinical trial. Lynx1 Fund offers $5.20/share buyout as biotech company explores merger and partnership options.